Norethindrone Acetate in the Medical Management of Adenomyosis
AbstractThe role of norethindrone acetate (NA) in the management of adenomyosis was evaluated with a retrospective chart review of 28 premenopausal women between 27–49 years of age presenting with moderate to severe pelvic pain and bleeding. Bleeding and dysmenorrhea scores were analyzed using paired T-tests. There was significant improvement of both dysmenorrhea and bleeding after treatment. Age showed no correlation with dysmenorrhea or bleeding. Low dose NA could be considered an effective, well-tolerated and inexpensive medical alternative to surgery for treating symptomatic adenomyosis. Large multicentric studies may help validate our findings. View Full-Text
Share & Cite This Article
Muneyyirci-Delale, O.; Chandrareddy, A.; Mankame, S.; Osei-Tutu, N.; Gizycki, H. Norethindrone Acetate in the Medical Management of Adenomyosis. Pharmaceuticals 2012, 5, 1120-1127.
Muneyyirci-Delale O, Chandrareddy A, Mankame S, Osei-Tutu N, Gizycki H. Norethindrone Acetate in the Medical Management of Adenomyosis. Pharmaceuticals. 2012; 5(10):1120-1127.Chicago/Turabian Style
Muneyyirci-Delale, Ozgul; Chandrareddy, Ashadeep; Mankame, Siddhi; Osei-Tutu, Nanna; Gizycki, Hans von. 2012. "Norethindrone Acetate in the Medical Management of Adenomyosis." Pharmaceuticals 5, no. 10: 1120-1127.